Description
Amyloïdose
Amyloïdose
- When AL amyloidosis meets the liver: integrating clinical insight and current understandingon 14 juin 2026
Ann Hematol. 2026 Jun 3. doi: 10.1007/s00277-026-07092-z. Online ahead of print.ABSTRACTLight chain (AL) amyloidosis is a plasma cell-derived protein misfolding disorder in which structurally […]
- AL Amyloidosis Presenting With Chronic Gastrointestinal Symptoms in a Patient With Lymphoplasmacytic Lymphomaon 14 juin 2026
ACG Case Rep J. 2026 May 22;13(5):e02148. doi: 10.14309/crj.0000000000002148. eCollection 2026 May.ABSTRACTAmyloidosis is a heterogeneous group of disorders caused by extracellular deposition of […]
- Crohn's Disease and Axial Spondyloarthritis: From Systemic Inflammation to Amyloidosison 14 juin 2026
J Clin Med. 2026 May 28;15(11):4188. doi: 10.3390/jcm15114188.ABSTRACTBackground: Crohn's disease (CD) is frequently complicated by extraintestinal manifestations, including axial spondyloarthritis […]
- Prolonged Infections and Inflammatory Diseases in Common Variable Immune Deficiency as a Cause of AA Amyloidosison 14 juin 2026
J Clin Med. 2026 May 22;15(11):4030. doi: 10.3390/jcm15114030.ABSTRACTBackground/Objectives: AA amyloidosis is a serious complication of chronic inflammation, which may arise in the setting of inborn […]
- A plasma protein signature for cerebral amyloid angiopathyon 14 juin 2026
Acta Neuropathol. 2026 May 20;151(1):59. doi: 10.1007/s00401-026-03030-5.ABSTRACTCerebral amyloid angiopathy (CAA) is a cerebrovascular disorder characterized by the deposition of amyloid-β (Aβ) in […]
- A rare case of orbital heavy chain amyloidosison 13 juin 2026
Orbit. 2026 Jun 7:1-4. doi: 10.1080/01676830.2026.2681055. Online ahead of print.ABSTRACTLocalized amyloidosis of the orbit and adnexa is a rare. This report explores the case of an elderly female […]
- Concurrent Tongue and Cervical Lymph Node Amyloidosis Without Systemic Diseaseon 13 juin 2026
Clin Case Rep. 2026 May 21;14(6):e72782. doi: 10.1002/ccr3.72782. eCollection 2026 Jun.ABSTRACTAmyloidosis of the head and neck is often associated with systemic involvement. However, this report […]
- AA Amyloidosis Resulting From Unintended Discontinuation of Rheumatoid Arthritis Therapy due to Cognitive Impairmenton 13 juin 2026
Clin Case Rep. 2026 May 26;14(6):e72822. doi: 10.1002/ccr3.72822. eCollection 2026 Jun.ABSTRACTAmyloid A (AA) amyloidosis is a serious complication of chronic inflammatory diseases, including […]
- Renal AA amyloidosis associated with inflammatory bowel diseaseon 13 juin 2026
BMC Nephrol. 2026 May 16. doi: 10.1186/s12882-026-04974-2. Online ahead of print.ABSTRACTINTRODUCTION: Renal AA amyloidosis is a rare but severe complication of inflammatory bowel disease (IBD), […]
- Multiple Myeloma Concomitant with AL Amyloidosis: Histopathological Aspects of the Common Plasma Cell Spectrumon 13 juin 2026
Int J Mol Sci. 2026 Jun 5;27(11):5120. doi: 10.3390/ijms27115120.ABSTRACTConcurrent multiple myeloma (MM) and AL amyloidosis is associated with the poorest outcomes among plasma cell dyscrasias and […]
- Gain-of-function Modulation of TREM2 and its Impact on Amyloid-beta and Tau Pathologies in Alzheimer's Disease: A Systematic Review and Meta-analysis of Animal Studieson 13 juin 2026
Mol Neurobiol. 2026 Jun 2;63(1):668. doi: 10.1007/s12035-026-05925-6.ABSTRACTAlzheimer's disease (AD) is characterized by amyloid-β (Aβ) deposition, hyperphosphorylated Tau accumulation, and […]
Atteintes cardiovasculaires
Atteintes cardiovasculaires
- Evidence of increased awareness in cardiac amyloidosis, but still room for improvementon 14 juin 2026
Eur J Intern Med. 2026 May 30:106985. doi: 10.1016/j.ejim.2026.106985. Online ahead of print.NO ABSTRACTPMID:42218044 | DOI:10.1016/j.ejim.2026.106985
- Cardiac amyloidosis: Disease overview and novel pathophysiologic insightson 14 juin 2026
J Nucl Cardiol. 2026 May;59S:102723. doi: 10.1016/j.nuclcard.2026.102723. Epub 2026 May 15.ABSTRACTCardiac amyloidosis (CA) has transitioned from a rare, frequently fatal disease to an increasingly […]
- Cardiac amyloidosis: Current and pipeline of therapies for the nuclear imageron 14 juin 2026
J Nucl Cardiol. 2026 May;59S:102727. doi: 10.1016/j.nuclcard.2026.102727. Epub 2026 May 15.ABSTRACTCardiac amyloidosis (CA) is characterized by cardiac amyloid fibril deposition leading to organ […]
- Recent updates in the management of atrial fibrillation in patients with cardiac amyloidosison 14 juin 2026
Future Cardiol. 2026 May 18:1-18. doi: 10.1080/14796678.2026.2671774. Online ahead of print.ABSTRACTLeft atrial myopathy in cardiac amyloidosis leads to structural, functional, and electrophysiologic […]
- Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders - The EXCALIBUR studyon 13 juin 2026
J Am Coll Cardiol. 2026 Apr 27:S0735-1097(26)06349-7. doi: 10.1016/j.jacc.2026.04.030. Online ahead of print.ABSTRACTBACKGROUND: Cardiac amyloidosis (CA) is a progressive infiltrative cardiomyopathy […]
- Prevalence and Burden of Cardiac Amyloidosis in a Population-Based Autopsy Cohorton 13 juin 2026
Circulation. 2026 Jun 9;153(23):1874-1876. doi: 10.1161/CIRCULATIONAHA.126.079522. Epub 2026 Jun 8.NO ABSTRACTPMID:42258576 | DOI:10.1161/CIRCULATIONAHA.126.079522
- Immunoglobulin A lambda multiple myeloma- related light-chain cardiac amyloidosis presenting with progressive heart failure with preserved ejection fraction: a multimodality imaging case reporton 13 juin 2026
Eur Heart J Case Rep. 2026 May 7;10(5):ytag288. doi: 10.1093/ehjcr/ytag288. eCollection 2026 May.ABSTRACTBACKGROUND: Cardiac involvement is the main determinant of prognosis in immunoglobulin […]
- Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersenon 13 juin 2026
Eur J Heart Fail. 2026 May 30:xuag168. doi: 10.1093/ejhf/xuag168. Online ahead of print.ABSTRACTAIMS: Eplontersen is an antisense oligonucleotide that suppresses hepatic production of circulating […]
Diagnostic et évaluation
Diagnostic et évaluation
- Beyond the Biopsy: Diagnosing Pleural Amyloidosis Through Fluid Cytologyon 14 juin 2026
Diagn Cytopathol. 2026 Jun 9. doi: 10.1002/dc.70157. Online ahead of print.NO ABSTRACTPMID:42262057 | DOI:10.1002/dc.70157
- High-performance multicenter Echocardiographic diagnostic score for Transthyretin Cardiac amyloidosis: results from the REACT-SP multicenter retrospective Cohort studyon 14 juin 2026
Heart Lung. 2026 Jun 12;79:102874. doi: 10.1016/j.hrtlng.2026.102874. Online ahead of print.ABSTRACTBACKGROUND: Early recognition of transthyretin cardiac amyloidosis (ATTR-CA) remains challenging […]
- Diagnostic Performance Evaluation of Clinical and AI Risk Models in Patients Referred for Cardiac Amyloidosis Testingon 14 juin 2026
J Am Soc Echocardiogr. 2026 May 13:S0894-7317(26)00219-1. doi: 10.1016/j.echo.2026.05.007. Online ahead of print.ABSTRACTBACKGROUND: To improve screening for cardiac amyloidosis (CA), several models […]
- Multimodality imaging in cardiac amyloidosis: When and how to combine nuclear techniques with echocardiography and cardiac magnetic resonance imagingon 13 juin 2026
J Nucl Cardiol. 2026 May;59S:102728. doi: 10.1016/j.nuclcard.2026.102728. Epub 2026 May 15.ABSTRACTEchocardiography and cardiac magnetic resonance (CMR) can demonstrate features of myocardial […]
- CSF Biomarker Profile of Cerebral Amyloid Angiopathy: Diagnostic Performance and Imaging Correlates in a Hospital-Based Neurology Cohorton 13 juin 2026
Eur J Neurol. 2026 May;33(5):e70613. doi: 10.1111/ene.70613.ABSTRACTBACKGROUND: Cerebral amyloid angiopathy (CAA) frequently co-occurs with Alzheimer's disease (AD), complicating diagnosis in […]
- Hepatic Amyloid Light-Chain Amyloidosis Incidentally Diagnosed via Endoscopic Ultrasound-Guided Liver Biopsyon 13 juin 2026
ACG Case Rep J. 2026 May 26;13(5):e02128. doi: 10.14309/crj.0000000000002128. eCollection 2026 May.ABSTRACTHepatic amyloid light-chain (AL) amyloidosis is characterized by amyloid protein deposition […]
- An era of precision: Emerging, research, and adjunct radiotracers for nuclear imaging of cardiac amyloidosison 13 juin 2026
J Nucl Cardiol. 2026 May;59S:102726. doi: 10.1016/j.nuclcard.2026.102726. Epub 2026 May 15.ABSTRACTCardiac amyloidosis (CA) has rapidly transitioned from an underrecognized cause of heart failure to […]
- Differential diagnosis of hypertrophic cardiomyopathy, fabry cardiomyopathy and cardiac amyloidosis: insights from right ventricular strain imaging echocardiographyon 13 juin 2026
Int J Cardiovasc Imaging. 2026 Jun 10. doi: 10.1007/s10554-026-03750-5. Online ahead of print.ABSTRACTPurpose This study aims to evaluate the diagnostic value of right ventricular (RV) myocardial […]
- Amyloid in Primary Hip Arthroplasty Specimens: An Opportunity for Early Detection of Amyloidosis?on 13 juin 2026
J Arthroplasty. 2026 May 13:S0883-5403(26)00505-X. doi: 10.1016/j.arth.2026.05.015. Online ahead of print.ABSTRACTBACKGROUND: Recent advances in pharmacologic therapies to treat amyloidosis demand […]
- Multimodal Artificial Intelligence for Cardiac Amyloidosis Diagnosis: Integrating Echocardiography With Clinical and Laboratory Data for Improved Detectionon 13 juin 2026
Circ Cardiovasc Imaging. 2026 May 27:e019610. doi: 10.1161/CIRCIMAGING.126.019610. Online ahead of print.ABSTRACTBACKGROUND: Cardiac amyloidosis (CA) is an underdiagnosed yet treatable cause of heart […]
- Brazilian consensus recommendations on the diagnosis and treatment of light chain amyloidosison 13 juin 2026
Hematol Transfus Cell Ther. 2026 Jun 2;48(3):106482. doi: 10.1016/j.htct.2026.106482. Online ahead of print.ABSTRACTINTRODUCTION: Systemic immunoglobulin light chain amyloidosis is characterized by […]
- Cardiac amyloid radionuclide imaging: Global perspective and future prioritieson 13 juin 2026
J Nucl Cardiol. 2026 May;59S:102725. doi: 10.1016/j.nuclcard.2026.102725. Epub 2026 May 15.ABSTRACTTransthyretin amyloid cardiomyopathy (ATTR-CM) has transitioned from a rare, untreatable condition […]
- Diagnostic Yield of Abdominal Wall Fat Pad Biopsy for Systemic Amyloidosis in a Low-Prevalence Referral Cohorton 13 juin 2026
Dermatol Pract Concept. 2026 Apr 1;16(2). doi: 10.5826/dpc.1602a6917.ABSTRACTINTRODUCTION: Systemic amyloidosis is a rare disorder characterized by extracellular amyloid deposition in tissues, […]
- The role of cardiac PET imaging in cardiac amyloidosison 13 juin 2026
Semin Nucl Med. 2026 May 30:S0001-2998(26)00118-2. doi: 10.1053/j.semnuclmed.2026.05.007. Online ahead of print.ABSTRACTCardiac amyloidosis is an increasingly recognized infiltrative cardiomyopathy […]
- Evaluation of the diagnostic value of dual-time-point, multi-parameter 99mTc-PYP imaging in diagnosing Transthyretin Cardiac Amyloidosison 13 juin 2026
Int J Cardiovasc Imaging. 2026 May 16. doi: 10.1007/s10554-026-03727-4. Online ahead of print.ABSTRACTObjective To assess the clinical value of dual-time-point planar imaging and SPECT/CT tomographic […]
- Risk-score performance for detecting transthyretin cardiac amyloidosis in severe aortic stenosis: a prospective cohort studyon 13 juin 2026
Front Cardiovasc Med. 2026 May 22;13:1773579. doi: 10.3389/fcvm.2026.1773579. eCollection 2026.ABSTRACTINTRODUCTION: The coexistence of transthyretin cardiac amyloidosis (ATTR-CA) and severe aortic […]
- A simple nomogram to help guide the diagnosis of cardiac amyloidosis in patients with heart failure with preserved ejection fractionon 13 juin 2026
Quant Imaging Med Surg. 2026 May 1;16(5):403. doi: 10.21037/qims-2025-1-2646. Epub 2026 Apr 14.ABSTRACTBACKGROUND: Cardiac amyloidosis (CA) has been recognized as a more frequent cause of heart […]
- Long-read Oxford Nanopore sequencing enables rapid, cost-effective, and comprehensive TTR genetic testing for hereditary transthyretin amyloidosison 13 juin 2026
Clin Chem Lab Med. 2026 May 20. doi: 10.1515/cclm-2026-0553. Online ahead of print.ABSTRACTOBJECTIVES: Hereditary transthyretin amyloidosis (ATTRv) is a rare autosomal dominant disorder caused by […]
- Pulmonary amyloidosis: clinicopathologic spectrum and diagnostic pitfalls in a 12-patient case serieson 13 juin 2026
J Thorac Dis. 2026 Apr 30;18(4):350. doi: 10.21037/jtd-2025-1-2730. Epub 2026 Mar 19.ABSTRACTBACKGROUND: Pulmonary amyloidosis is a rare, underrecognized manifestation of amyloid disease that may […]
- Systematic review of curcumin-based optical imaging for amyloid-beta detection in Alzheimer's disease modelson 13 juin 2026
Curr J Neurol. 2025 Apr 4;24(2):168-176. doi: 10.18502/cjn.v24i2.20693.ABSTRACTBackground: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by amyloid-beta (Aβ) plaque […]
Interventions et pronostic
Interventions et pronostic
- The prognostic value of red blood cell distribution width in AL amyloidosison 14 juin 2026
Amyloid. 2026 May 16:1-4. doi: 10.1080/13506129.2026.2671953. Online ahead of print.NO ABSTRACTPMID:42141964 | DOI:10.1080/13506129.2026.2671953
- Retrospective cohort study of treatment with BCL-2 inhibitor venetoclax in advanced AL amyloidosison 14 juin 2026
Haematologica. 2026 Jun 11. doi: 10.3324/haematol.2025.288635. Online ahead of print.ABSTRACTNot available.PMID:42273946 | DOI:10.3324/haematol.2025.288635
- Transthyretin and Vitamin A Metabolism: A Review for the Cardiac Amyloidosis Specialiston 14 juin 2026
J Cardiovasc Dev Dis. 2026 May 12;13(5):205. doi: 10.3390/jcdd13050205.ABSTRACTTransthyretin (TTR) amyloidosis is a systemic, progressive, and fatal disease. TTR is integral in vitamin A (retinol) […]
- Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosison 14 juin 2026
Am J Hematol. 2026 Jun 7. doi: 10.1002/ajh.70371. Online ahead of print.ABSTRACTHigh dose melphalan (HDM) with autologous stem cell transplant is an established treatment for systemic light chain […]
- Efficacy of diflunisal for hereditary transthyretin amyloidosis: the Swedish real-world experienceon 14 juin 2026
Amyloid. 2026 Jun 3:1-7. doi: 10.1080/13506129.2026.2678340. Online ahead of print.ABSTRACTBACKGROUND: Diflunisal has been shown to slow the progression of hereditary transthyretin (ATTRv) […]
- Attenuated prognostic discrimination among Mayo stages I-IIIa and improved survival in stage IIIb in the daratumumab era: a real-world study of newly diagnosed AL amyloidosison 14 juin 2026
Leuk Lymphoma. 2026 Jun 7:1-9. doi: 10.1080/10428194.2026.2677040. Online ahead of print.ABSTRACTDaratumumab-based regimens have become first-line therapy for immunoglobulin light-chain (AL) […]
- Pharmacological Interventions for Hereditary Transthyretin-Related Amyloidosis With Polyneuropathy: Systematic Review and Network Meta-Analysison 13 juin 2026
Eur J Neurol. 2026 Jun;33(6):e70627. doi: 10.1111/ene.70627.ABSTRACTBACKGROUND: We used network meta-analyses to evaluate the pharmacological interventions for Hereditary Transthyretin-related […]
- Mortality in octogenarian patients with transthyretin amyloidosis treated with tafamidis: a systematic review and meta-analysison 13 juin 2026
Orphanet J Rare Dis. 2026 Jun 9. doi: 10.1186/s13023-026-04422-2. Online ahead of print.ABSTRACTBACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) predominantly affects older adults, and […]
- Comments on "Neurological efficacy and safety of RNA therapeutics in hereditary transthyretin amyloidosis: a systematic review and meta-analysis of randomized controlled trials"on 13 juin 2026
Ther Adv Cardiovasc Dis. 2026 Jan-Dec;20:17539447261453501. doi: 10.1177/17539447261453501. Epub 2026 May 21.NO ABSTRACTPMID:42165439 | DOI:10.1177/17539447261453501
Expériences des patients et des institutions
Expériences des patients et des institutions
- Clinical Practice and Diagnostic Trends in Hereditary Transthyretin Amyloidosis: A 25-Year Observational Studyon 14 juin 2026
Medicina (Kaunas). 2026 May 7;62(5):907. doi: 10.3390/medicina62050907.ABSTRACTBackground and Objectives: Hereditary transthyretin amyloidosis (ATTRv), a multisystemic disorder caused by […]
- On the crossroads of interdisciplinary medicine in amyloidosis - study protocol for a single-center interdisciplinary registry studyon 14 juin 2026
PLoS One. 2026 Jun 2;21(6):e0350084. doi: 10.1371/journal.pone.0350084. eCollection 2026.ABSTRACTBACKGROUND: Systemic amyloidosis comprises a heterogeneous group of rare diseases characterised by […]
Pour obtenir les documents
L’accès au texte intégral des documents est restreint au personnel et aux médecins du CHUM en fonction des abonnements de la bibliothèque. Certains documents sont en accès libre sur le web.
Si vous êtes branchés sur le réseau CHUM :
Cliquer sur les liens fournis pour chaque référence pour vérifier la disponibilité du texte intégral.
Pour les articles provenant de PubMed, cliquer préalablement sur le lien suivant pour afficher la disponibilité du document.
Si vous êtes dans un autre établissement et que vous n’arrivez pas à accéder au texte intégral d’un article à partir du lien donné, vérifier auprès de la bibliothèque de votre institution en donnant la référence complète du document.
|
Avis de non-responsabilité
Le contenu des veilles informationnelles ou stratégiques (ci-après appelée « Veilles ») est mis à votre disposition à titre informatif pour un usage personnel exclusif. Tout usage commercial du contenu des Veilles est strictement interdit. Tous les éléments, articles, rapports ou toute autre source d’information figurant dans les Veilles, vous sont fournis « tels quels », sans garantie d’aucune sorte. Eu égard aux propos tenus dans les articles et les rapports sélectionnés pour les Veilles, le CHUM n’offre aucune garantie notamment d’exhaustivité, de fiabilité, d’actualité et d’exactitude.Le CHUM ne pourra en aucun cas être tenu responsable envers quiconque de tout dommage quel qu’il soit, même ceux directs, encouru notamment des suites de toute réclamation, action ou poursuite découlant, même directement, de l’utilisation de ces Veilles.
Les Veilles contiennent des liens vers des sites Web créés et mis à jour par des tierces parties. Ces liens sont fournis pour la commodité des utilisateurs seulement. Le CHUM n’endosse et ne garantit, ni explicitement ni implicitement, l’exactitude ou l’intégralité ni du contenu de ces hyperliens ni des opinions qui y sont exprimées. Le CHUM n’assume aucune responsabilité à l’égard de ces sites Web externes.
Le CHUM prend tous les moyens raisonnables afin de respecter les droits de propriété intellectuelle afférents au contenu des Veilles et aux modalités du prêt entre bibliothèques, émises par l’Université de Montréal. Le contenu des Veilles, incluant la manière dont il est présenté, sont notamment protégés par la Loi sur le droit d’auteur (L.R.C. (1985), ch. C-42). Le CHUM ne donne aucune garantie et ne fait aucune déclaration à l’effet que le contenu de ces veilles n’enfreint aucun droit d’une autre personne ou entité. Le téléchargement, la reproduction en un seul exemplaire ou le tirage sur papier des Veilles ne sont autorisés qu’à des fins de sauvegarde et pour un usage privé et non commercial. Tout téléchargement, reproduction, édition, diffusion sur Internet, utilisation à des fins commerciales ou publiques, distribution, publication sur un autre site ou sur quelque autre forme ainsi que toute autre utilisation est strictement interdite, à moins d’être faite dans le respect des règles de propriété intellectuelle applicables. |


